Table 1.
Main baseline patient characteristics.
| Clinical characteristics | Condition | N = 123 |
|---|---|---|
| Age (years), median (IQR) | — | 51 (48–55) |
| Sex, n (%) | Male | 102 (82.9) |
| Female | 21 (17.1) | |
| HIV viral load, n (%) | Undetectable | 119 (96.7) |
| Detectable | 4 (3.3) | |
| CD4 count at inclusion study (cell/mL), median (IQR) | — | 560 (396–726.5) |
| Use of ART, n (%) | Yes | 122 (99.2) |
| No | 1 (0.8) | |
| HCV genotype, n (%) | 1 | 59 (48) |
| 2 | 4 (3.2) | |
| 3 | 54 (43.9) | |
| 4 | 6 (4.9) | |
| Type of HCV therapya | Peg-IFN + RBV | 102 (82.9) |
| DAAb + Peg-IFN + RBV | 20 (16.3) | |
| IFN-free | 1 (0.8) | |
| Liver stiffness (kPa) at inclusion in study, median (IQR) | — | 6 (4.7–7.7) |
| Liver stiffness (kPa) at SVR, median (IQR) | — | 7.2 (5.4–11.7) |
| Time from SVR (months), median (IQR) | — | 51 (27–76) |
Interquertile range (IQR); n (number of cases); human immunodeficiency virus (HIV); antiretroviral therapy (cART); hepatitis C virus (HCV); pegylated interferon (Peg-IFN); ribavirin (RBV); direct-acting antiviral (DAA).
aHCV therapy which induced SVR;
bdaclatasvir (n = 7); telaprevir or boceprevir (n = 13).